From: Safety and feasibility of fasting in combination with platinum-based chemotherapy
Toxicity | 24 h | 48 h | 72 h | |
---|---|---|---|---|
# (%) | # (%) | # (%) | ||
N = 6 | N = 7 | N = 7 | ||
Constitutional/General | ||||
Fatigue | Grade 1 or 2 | 6 (100 %) | 5 (71 %) | 6 (86 %) |
Alopecia | Grade 1 | 6 (100 %) | 5 (71 %) | 7 (100 %) |
Gastrointestinal | ||||
Nausea | Grade 1 or 2 | 6 (100 %) | 6 (86 %) | 3 (43 %) |
Vomiting | Grade 1 or 2 | 5 (83 %) | 3 (43 %) | 0 |
Constipation | Grade 1 or 2 | 3 (50 %) | 2 (28 %) | 3 (43 %) |
Diarrhea | Grade 1 or 2 | 2 (33 %) | 0 | 4 (57 %) |
Grade 3 | 0 | 1 (14 %) | 0 | |
Hematologic | ||||
Neutropenia | Grade 1 or 2 | 1 (17 %) | 3 (43 %) | 1 (14 %) |
Grade 3 or 4 | 4 (67 %) | 1 (14 %) | 2 (29 %) | |
Thrombocytopenia | Grade 1 or 2 | 4 (67 %) | 1 (14 %) | 1 (14 %) |
Grade 3 or 4 | 0 | 1 (14 %) | 0 | |
Laboratory/Metabolic | ||||
Hyponatremia | Grade 1 | 1 (17 %) | 1 (14 %) | 1 (14 %) |
Grade 3 | 1 (17 %) | 0 | 0 | |
Hypokalemia | Grade 1 | 1 (17 %) | 2 (28 %) | 0 |
Hyperglycemia | Grade 1 or 2 | 4 (67 %) | 1 (14 %) | 0 |
Elevated AST/ALT | Grade 1 | 4 (67 %) | 0 | 3 (43 %) |
Neurologic | ||||
Peripheral Neuropathy | Grade 1 | 3 (50 %) | 1 (14 %) | 1 (14 %) |
Dizziness | Grade 1 or 2 | 1 (17 %) | 5 (71 %) | 2 (29 %) |